Prodromal α-Synucleinopathies Consortium (PαSS) (U19 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This funding opportunity announcement (FOA) invites applications to develop a multisite, longitudinal, prospective study of idiopathic REM sleep behavior disorder (iRBD) as a prodromal phase of α-synuclein neurodegenerative disorders.

Deadlines:

  • Letter of Intent Due Date(s): May 17, 2020
  • Application Due Date(s): June 17, 2020  ​

RFA-AG-21-013 Expiration Date June 18, 2020

Agency Website

Eligibility Requirements

A multiple-principal investigator (PI) format is required, with one or more PIs with expertise in sleep disorders and one or more PIs with expertise in neurodegenerative diseases, particularly Parkinson’s disease and Lewy Body Dementia  

Amount

$15,000,000

Amount Description

Application budgets are limited to $3 million in direct costs per year.

The maximum project period is 5 years. 

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science

External Deadline

June 17, 2020